VTGN - VistaGen stock down 7% on disappointing FY result

VistaGen Therapeutics (NASDAQ:VTGN) stock down 7.6% after the company posted lower-than-expected full year result. The company's revenue rose 1.7% Y/Y to $1.11M, but missed estimates by $0.21M. The company's FY GAAP EPS of -$0.25 missed estimates by $0.03 as costs increased. Research and development expense increased to $35.4M, from $11.9M , due to the preparation, initiation and continuation of the various clinical trials for social anxiety disorder treatment. General and administrative expense increased to about $13.5M. The company had cash of $68.1M as of March 31. The company said it expects topline results from phase 3 trial of PH94B in social anxiety disorder in mid-2022. Presentation

For further details see:

VistaGen stock down 7% on disappointing FY result